直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Federal Circuit Confirms PTAB Need Not Address Every Claim Raised in a Petition

February 22, 2016

Authored and Edited by Alex Kwan-Ho Chung, Ph.D.

In an appeal from a Patent Trial and Appeal Board (PTAB) decision, a split Federal Circuit panel affirmed that (1) the final order of the PTAB need not address every claim raised in the petition for review, and (2) the PTAB did not err in denying Mentor’s motion to amend and substitute claims. Synopsys, Inc. v. Mentor Graphics Corp. Nos. 2014-1516, -1530 (Fed. Cir. February 10, 2016).

First, the Court held that there is “no statutory requirement that the Board’s final decision address every claim raised in a petition for inter partes review.” Guided by text of the statute, the Court distinguished the claims that must be addressed in the final decision from the claims raised in the petition, and found that the PTAB can pick and choose which claims to institute on a claim-by-claim basis. Moreover, the Court saw little sense in requiring the PTAB to issue final decisions on validity of uninstituted patent claims without the benefit of argument and record created after institution.

Second, the Court held that the PTAB correctly assigned the burden of proving patentability to the patent owner for the claims that were not challenged in the petition but were proposed for substitution by the patent owner. Such finding was consistent, the Court reasoned, with the case law where the PTAB placed burden of proof on patent owner based on the prior art of record, as was the case here. Further, statutory language placed the burden of proof on petitioner specifically for claims that were challenged in a petition, the Court found.

In a lengthy dissent, Judge Newman advanced four arguments. First, allowing the PTAB to pick and choose which claims to institute creates an “absence of finality negat[ing] the AIA’s purpose of providing an alternative and efficient forum for resolving patent validity issues.” Second, substantive rulings made during the institution determination should be appealable if such rulings were material to the final decision on validity. Third, the PTO’s practice of assigning the institution decision to the PTAB is contrary to the AIA, which assigns the decision to institute to the Director and assigns the trial and final decision to the PTAB. Finally, the PTO’s practice of regularly denying amendments in IPR proceedings undermines the balance struck between allowing amendment and lowering the evidentiary standard of invalidity applied by the courts.

Tags

37 C.F.R. § 42.108, United States Court of Appeals for the Federal Circuit (CAFC), Synopsys, United States Patent and Trademark Office (USPTO)

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP